• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300966.SZ
Share

Hubei Goto Biopharm Group Co., Ltd. Stocks

CN¥ 29.24Last Updated 15.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

CN¥ 512.61M

CN¥ 29.24
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hubei Goto Biopharm Co.,Ltd. is a Chinese enterprise specializing in the manufacture and distribution of active pharmaceutical ingredients (APIs) and intermediate compounds for steroid hormones. Its product line features essential starting materials such as 9a-hydroxy-4-androstenedione (9a-OHAD), bisnoralcohol (BA), sitolactone, 1,4-androstadienedione (ADD), and 4-androstenedione (4-AD). The company also provides a variety of intermediates, including those for estrogens, progesterone, non-steroidal substances, various other hormones, and corticosteroids. Furthermore, Hubei Goto Biopharm supplies additional raw materials for the pharmaceutical industry. The firm was established in Yicheng, China, in 2006.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 18:04

Wholesale prices in the U.S. fell in June—a development the market did not expect

15.07.2026 17:30

Assets under management at BlackRock exceeded $15 trillion for the first time

15.07.2026 17:00

OpenAI's first device will be a "smart speaker." Will this create competition for Apple?

15.07.2026 16:35

The stock price of Stride, a small edtech company, has plummeted. The reason is Anthropic

15.07.2026 16:00

"There Aren't Enough IT Budgets to Go Around": What Does IBM's Historic Plunge Mean for the Stock Market?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026